An intervention study conducted by Aye et al. in a mouse model of obesity in pregnancy shows that using synthetic adiponectin receptor agonist may be a helpful intervention treatment to increase functional adiponectin on maternal and placental tissues to reduce the metabolic and hormonal complications due to maternal obesity and GDM (24). This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.